Select Bibliography

Filter by any of these (after searching):

Holstein, Sarah

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 15 items

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM)

Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary-not-in-original - Meta-Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance)

Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Chhabra, Saurabh , Callander, Natalie S. , Costa, Luciano J. ... - ASH - Blood - 2021

Abstract - Secondary-not-in-original - Primary - Myeloma - AFT-29 (GRIFFIN)

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104

Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma

Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020

Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)

Kaufman, Jonathan L. , Laubach, Jacob , Sborov, Douglas W. ... - ASH - Blood - 2020

Abstract - Primary - Long-Term-Followup - Myeloma - AFT-29 (GRIFFIN)

Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB

McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017

Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance)

McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018

Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Nooka, Ajay K. , Kaufman, Jonathan L. , Rodriguez, Cesar ... - - Blood Cancer J - 2022

Manuscript - Secondary-not-in-original - Primary - Myeloma - AFT-29 (GRIFFIN)

Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN

Sborov, Douglas W. , Laubach, Jacob , Kaufman, Jonathan L. ... - IMS - - 2022

Abstract - No-Endpoint - Other - Myeloma - AFT-29 (GRIFFIN)

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - - Blood - 2020

Manuscript - Primary - Primary - Myeloma - AFT-29 (GRIFFIN)